Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Susan M Domchek,Carol Aghajanian,Ronnie Shapirafrommer,Rita K Schmutzler,M William Audeh,Michael Friedlander,Judith Balmana,Gillian Mitchell,Georgeta Fried,Salomon M Stemmer,Ayala Hubert,Ora Rosengarten,Niklas Loman,Jane D Robertson,Helen Mann,Bella Kaufman

Gynecologic Oncology（2016）

引用 245|浏览24

暂无评分

摘要

•Women with BRCA1/2m ovarian cancer and >3 chemotherapy regimens had clinical benefit from olaparib•Response rate was higher for patients with platinum-sensitive versus platinum-resistant tumors•Duration of response was similar for platinum-sensitive versus platinum-resistant tumors•No new safety findings were identified in this heavily pretreated population

查看译文

关键词

Olaparib,Ovarian cancer,BRCA1/2 mutation,Phase II

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要